首站-论文投稿智能助手
典型文献
Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches
文献摘要:
Non-alcoholic fatty liver disease (NAFLD) denotes a spectrum of fatty liver disease in individuals without significant alcohol consumption. NAFLD is set to be the most common etiology of serious liver diseases in numerous nations when accompanied by obesity and type 2 diabetes. It is further histologically categorized into the non-alcoholic fatty liver (NAFL; steatosis without hepatocellular injury) and non-alcoholic steatohepatitis (NASH) which is characterized by the coexistence of hepatic steatosis and inflammation and is accompanied by hepatocyte injury (ballooning), either with or without fibrosis. NAFL is considered the benign and reversible stage arising from the excessive accumulation of triglycerides in hepatocytes. However, NASH is a more progressive stage of NAFLD, due to the increased risks of evolving more serious diseases such as cirrhosis, hepatocellular carcinoma. This concept, however, has been lately challenged by a hypothesis of multiple parallel hits of NAFLD, in which steatosis and NASH are separate entities rather than two points of the NAFLD spectrum, not only from a set of histological patterns but also from a pathophysiological perspective. The current review highlights the epidemiology and pathophysiology of NAFLD, and its progression towards steatohepatitis, with special focus on the novel imminent therapeutic approaches targeting the molecular aspects and the pathogenic pathways involved in the development, and progression of NAFLD.
文献关键词:
作者姓名:
Rehab F.Abdel-Rahman
作者机构:
Department of Pharmacology,Medical Research and Clinical Studies Institute,National Research Centre,12622-Dokki,Giza,Egypt
引用格式:
[1]Rehab F.Abdel-Rahman-.Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches)[J].亚太热带生物医学杂志(英文版),2022(03):99-114
A类:
B类:
Non,alcoholic,fatty,liver,Epidemiology,pathophysiology,update,therapeutic,approaches,NAFLD,denotes,spectrum,individuals,without,significant,consumption,set,most,common,etiology,serious,diseases,numerous,nations,when,accompanied,by,obesity,type,diabetes,It,further,histologically,categorized,into,steatosis,hepatocellular,injury,steatohepatitis,NASH,which,characterized,coexistence,hepatic,inflammation,ballooning,either,fibrosis,considered,benign,reversible,stage,arising,from,excessive,accumulation,triglycerides,hepatocytes,However,more,progressive,due,increased,risks,evolving,such,cirrhosis,carcinoma,This,concept,however,has,been,lately,challenged,hypothesis,multiple,parallel,hits,are,separate,entities,rather,than,two,points,only,patterns,but,also,pathophysiological,perspective,current,review,highlights,epidemiology,progression,towards,special,focus,novel,imminent,targeting,molecular,aspects,pathogenic,pathways,involved,development
AB值:
0.585032
相似文献
Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation
Shuyin Bao;Xiuzhi Wang;Qianqian Ma;Chengxi Wei;Jixing Nan;Wuliji Ao-Institute of Pharmaceutical Chemistry and Pharmacology,Inner Mongolia Minzu University,Tongliao 028000,China;Inner Mongolia Key Laboratory of Mongolian Medicine Pharmacology for Cardio-Cerebral Vascular System,Tongliao 028000,China;Jilin Key Laboratory for Traditional Chinese Korean Medicine,College of Pharmacy,Yanbian University,Yanji 133002,China;Department of Medicines and Foods,Tongliao Vocational College,Tongliao 028000,China;Research and development center,Inner Mongolia Research Institute of Traditional Mongolian Medicine Engineering Technology,Tongliao 028000,China;Mongolian Medicine R&D National Local Union Engineering Research Center,Inner Mongolia Minzu University,Tongliao 028000,China
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD:A promising drug Potentilla discolor Bunge
Longshan Ji;Qian Li;Yong He;Xin Zhang;Zhenhua Zhou;Yating Gao;Miao Fang;Zhuo Yu;Robim M.Rodrigues;Yueqiu Gao;Man Li-Laboratory of Cellular Immunity,Institute of Clinical Immunology,Shanghai Key Laboratory of Traditional Chinese Medicine,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Key Laboratory of Liver and Kidney Diseases(Shanghai University of Traditional Chinese Medicine),Ministry of Education,Shanghai 201203,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Department of Hepatopathy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of in Vitro Toxicology and Dermato-Cosmetology,Faculty of Medicine and Pharmacy,Vrije Universiteit Brussel,Brussels 1000,Belgium
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong;Dongjie Li;Hongbo Meng;Diyang Sun;Xiuting Lan;Min Ni;Jiawei Ma;Feiyan Zeng;Sijia Sun;Jiangtao Fu;Guoqiang Li;Qingxin Ji;Guoyan Zhang;Qirui Shen;Yuanyuan Wang;Jiahui Zhu;Yi Zhao;Xujie Wang;Yi Liu;Shenxi Ouyang;Chunquan Sheng;Fuming Shen;Pei Wang-Department of Pharmacy,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Nuclear Medicine,Tongji University School of Medicine,Shanghai 200072,China;Department of General Surgery,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Department of Pharmacology,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China;Department of Pharmacy,Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China;Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University,Shanghai 200241,China;Chemical Biology Research Center School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325000,China;Department of Medicinal Chemistry,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China
Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway
Yi-kuan Wu;Zheng-nan Ren;Sheng-long Zhu;Yun-zhou Wu;Gang Wang;Hao Zhang;Wei Chen;Zhao He;Xian-long Ye;Qi-xiao Zhai-State Key Laboratory of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Medicine,Jiangnan University,Wuxi 214122,China;College of Life Science,Northeast Agricultural University,Harbin 150038,China;National Engineering Research Center for Functional Food,Jiangnan University,Wuxi 214122,China;Shandong Key Laboratory of Endocrinology and Lipid Metabolism,Jinan 250021,China;School of Medicine,Shandong University,Jinan 250012,China;Ganjiang Chinese Medicine Innovation Center,Nanchang 330000,China
Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells
Hao Shen;Han Yu;Qian-yu Li;Ya-ting Wei;Jing Fu;Hui Dong;Dan Cao;Lin-na Guo;Lei Chen;Yuan Yang;Ying Xu;Meng-chao Wu;Hong-yang Wang;Yao Chen-International Cooperation Laboratory on Signal Transduction,National Center for Liver Cancer,Ministry of Education Key Laboratory on signaling Regulation and Targeting Therapy of Liver Cancer,Shanghai Key Laboratory of Hepato-biliary Tumor Biology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University/NAVAL Medical University,Shanghai 200433,China;Department of Pathology,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Metabolism and Integrative Biology,Fudan University,Shanghai 200438,China;Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。